Literature DB >> 18329759

Immunization with virus-like particles of enterovirus 71 elicits potent immune responses and protects mice against lethal challenge.

Yao-Chi Chung1, Mei-Shang Ho, Jaw-Chin Wu, Wei-Jheng Chen, Jen-Huang Huang, Szu-Ting Chou, Yu-Chen Hu.   

Abstract

Enterovirus 71 (EV71) is an etiologic agent responsible for seasonal epidemics of hand-foot-and-mouth disease and causes outbreaks with significant mortality among young children. To develop the vaccine, we have produced and purified the EV71 virus-like particle (VLP) that resembles the authentic virus in appearance, capsid structure and protein composition. In this study, we further evaluated the potential of VLP as a vaccine by comparing the humoral and cellular immune responses elicited by the purified VLP, denatured VLP and heat-inactivated EV71 virus. After immunization of BALB/c mice, EV71 VLP induced potent and long-lasting humoral immune responses as evidenced by the high total IgG titer and neutralization titer. The splenocytes collected from the VLP-immunized mice exhibited significant cell proliferation and produced high levels of IFN-gamma, IL-2 and IL-4 after stimulation, indicating the induction of Th1 and Th2 immune responses by VLP immunization. More importantly, the VLP immunization of mother mice conferred protection (survival rate up to 89%) to neonatal mice against the lethal (1000 LD(50)) viral challenge. Compared with the VLP immunization, immunization with denatured VLP and heat-inactivated EV71 elicited lower neutralization titers and conferred less effective protection to newborn mice, although they induced comparable levels of total IgG and cellular immune responses. These data collectively indicate the importance of the preservation of VLP structure and implicate the potential of VLP as a vaccine to prevent EV71 infection.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18329759     DOI: 10.1016/j.vaccine.2008.01.058

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  78 in total

1.  Antibodies to P-selectin glycoprotein ligand-1 block dendritic cell-mediated enterovirus 71 transmission and prevent virus-induced cells death.

Authors:  Xiao-Xin Ren; Chuan Li; Si-Dong Xiong; Zhong Huang; Jian-Hua Wang; Hai-Bo Wang
Journal:  Virulence       Date:  2015-09-23       Impact factor: 5.882

2.  Analysis of the Th1/Th2 reaction in the immune response induced by EV71 inactivated vaccine in neonatal rhesus monkeys.

Authors:  Yan Liang; Xiaofang Zhou; Erxia Yang; Jing Pu; Yanchun Che; Jingjing Wang; Na Ma; Longding Liu; Dong Ding; Donghong Tang; Dong Sheng; Lixian Yang; Hongling Zhao; Chenghong Dong; Qihan Li
Journal:  J Clin Immunol       Date:  2012-05-15       Impact factor: 8.317

3.  EV71 infection correlates with viral IgG preexisting at pharyngo-laryngeal mucosa in children.

Authors:  Jingchang Xue; Yaoming Li; Xiaoyi Xu; Jie Yu; Hu Yan; Huimin Yan
Journal:  Virol Sin       Date:  2015-03-20       Impact factor: 4.327

4.  Immunogenicity and protective efficacy of an EV71 virus-like particle vaccine against lethal challenge in newborn mice.

Authors:  Shiyang Sun; Fan Gao; Qunying Mao; Jie Shao; Liping Jiang; Dawei Liu; Yiping Wang; Xin Yao; Xing Wu; Bo Sun; Dandan Zhao; Youlei Ma; Jingcai Lu; Wei Kong; Chunlai Jiang; Zhenglun Liang
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

5.  Cryo-electron microscopy study of insect cell-expressed enterovirus 71 and coxsackievirus a16 virus-like particles provides a structural basis for vaccine development.

Authors:  Minqing Gong; Hongtao Zhu; Jun Zhou; Chunting Yang; Jing Feng; Xiaojun Huang; Gang Ji; Honglin Xu; Ping Zhu
Journal:  J Virol       Date:  2014-03-26       Impact factor: 5.103

6.  Evaluation of monovalent and bivalent vaccines against lethal Enterovirus 71 and Coxsackievirus A16 infection in newborn mice.

Authors:  Shiyang Sun; Liping Jiang; Zhenglun Liang; Qunying Mao; Weiheng Su; Huafei Zhang; Xiaojun Li; Jun Jin; Lin Xu; Dandan Zhao; Peihu Fan; Dong An; Ping Yang; Jingcai Lu; Xiuping Lv; Bo Sun; Fei Xu; Wei Kong; Chunlai Jiang
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

Review 7.  Progress on the research and development of human enterovirus 71 (EV71) vaccines.

Authors:  Zhenglun Liang; Qunying Mao; Fan Gao; Junzhi Wang
Journal:  Front Med       Date:  2012-12-17       Impact factor: 4.592

8.  The cross-reactivity of the enterovirus 71 to human brain tissue and identification of the cross-reactivity related fragments.

Authors:  Chun Shi Jia; Jiang Ning Liu; Wan Bo Li; Chun Mei Ma; Shu Zhu Lin; Yi Hao; Xue Zhong Gao; Xiao Lin Liu; Yan Feng Xu; Lian Feng Zhang; Chuan Qin
Journal:  Virol J       Date:  2010-02-22       Impact factor: 4.099

9.  Formaldehyde-inactivated whole-virus vaccine protects a murine model of enterovirus 71 encephalomyelitis against disease.

Authors:  Kien Chai Ong; Shamala Devi; Mary Jane Cardosa; Kum Thong Wong
Journal:  J Virol       Date:  2010-01       Impact factor: 5.103

10.  A replication-incompetent Rift Valley fever vaccine: chimeric virus-like particles protect mice and rats against lethal challenge.

Authors:  Robert B Mandell; Ramesh Koukuntla; Laura J K Mogler; Andrea K Carzoli; Alexander N Freiberg; Michael R Holbrook; Brian K Martin; William R Staplin; Nicholas N Vahanian; Charles J Link; Ramon Flick
Journal:  Virology       Date:  2009-11-24       Impact factor: 3.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.